The HER2-positive breast cancers with heterogeneous patterns of HER2 overexpression and gene amplification studied here were all ER-positive, and most were of high histologic grade (75%) and harbored somatic TP53 mutations (75%). Here, TP53 is linked to breast carcinoma.